ORAL LORAZEPAM PREVENTS SEIZURE DURING HIGH-DOSE BUSULFAN IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A Prospective Study

被引：8

作者：

Hamidieh, Amir Ali ^{[2
]}

Hamedani, Ravak ^{[1
]}

Hadjibabaie, Molouk ^{[1
]}

Amini, Mohsen ^{[3
]}

Sadrai, Sima ^{[4
]}

Ghavamzadeh, Ardeshir ^{[2
]}

机构：

[1] Univ Tehran Med Sci, Dept Clin Pharm, Fac Pharm, Tehran, Iran

[2] Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, Iran

[3] Univ Tehran Med Sci, Dept Med Chem, Fac Pharm, Tehran, Iran

[4] Univ Tehran Med Sci, Dept Pharmacokinet, Fac Pharm, Tehran, Iran

来源：

PEDIATRIC HEMATOLOGY AND ONCOLOGY | 2010年 / 27卷 / 07期

关键词：

anticonvulsants; busulfan; hematopoietic stem cell transplantation; lorazepam; MARROW TRANSPLANTATION; ACUTE-LEUKEMIA; CYCLOPHOSPHAMIDE; PROPHYLAXIS; PHARMACOKINETICS;

D O I：

10.3109/08880018.2010.496895

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-dose Busulfan in combination chemotherapy has been used commonly for hematopoietic stem cell transplantation. It crosses the blood-brain barrier and could cause seizure. Benzodiazepines have been used as anticonvulsant prophylaxis. This is a prospective study using oral lorazepam together with busulfan-based conditioning regimen in 30 children undergoing hematopoietic stem cell transplantation. The dose of lorazepam used ranged from 0.017 to 0.039 mg/kg (median = 0.026 mg/kg) per dose. None of the patients developed seizure while receiving oral lorazepam or within 72 hours of the last dose of Busulfan. Oral lorazepam was tolerated by the patients, but all patients needed dose reduction due to some adverse effects. In the authors' experience, oral lorazepam is a useful anticonvulsant prophylaxis for children receiving high-dose busulfan.

引用

页码：529 / 533

页数：5

共 15 条

[1] TOXICOLOGICAL REVIEW OF BUSULFAN (MYLERAN) [J].

BISHOP, JB ;

WASSOM, JS .

MUTATION RESEARCH, 1986, 168 (01) :15-45

[2] Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan [J].

Caselli, D. ;

Ziino, O. ;

Bartoli, A. ;

Santangelo, G. ;

Vanadia, F. ;

Arico, M. .

BONE MARROW TRANSPLANTATION, 2008, 42 (02) :135-136

[3] Lorazepam for seizure prophylaxis during high-dose busulfan administration [J].

Chan, KW ;

Mullen, CA ;

Worth, LL ;

Choroszy, M ;

Koontz, S ;

Tran, H ;

Slopis, J .

BONE MARROW TRANSPLANTATION, 2002, 29 (12) :963-965

[4] INFLUENCE OF PROPHYLACTIC ANTICONVULSANT THERAPY ON HIGH-DOSE BUSULFAN KINETICS [J].

HASSAN, M ;

OBERG, G ;

BJORKHOLM, M ;

WALLIN, I ;

LINDGREN, M .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 33 (03) :181-186

[5]

HOBBS JR, 1986, BONE MARROW TRANSPL, V1, P201

[6]

LIN KH, 1986, BONE MARROW TRANSPL, V1, P115

[7]

MARCUS RE, 1984, LANCET, V2, P1463

[8]

Meloni G, 1995, HAEMATOLOGICA, V80, P532

[9] AN INTERACTION BETWEEN CYTOSTATIC AND ANTICONVULSANT DRUGS [J].

NEEF, C ;

DEVOOGDVANDERSTRAATEN, I .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (04) :372-375

[10]

SANTOS GW, 1989, BONE MARROW TRANSPL, V4, P236

← 1 2 →